ClinicalTrials.gg
CompletedNCT02055352COMBINEUpdated Apr 18, 2017Results posted

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD

A Phase 4 interventional study of Budesonide and Fluticasone in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 25 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
13th of 43
222 · median 99
Started
2014
with 3 others
Phase 4
18 of 43
2 open now
Registered
17th of 43
by date
Lead sponsor
2 of 43
Novartis Pharmaceuticals

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 13th largest by enrollment, is one of 4 that started in 2014, is one of 18 in phase 4, and was the 17th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

To demonstrate the free combination of budesonide and indacaterol is as efficacious as fluticasone and salmeterol in patients with COPD

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed
  • Outpatients with stable groups C and D according to the 2011 GOLD Guidelines.
  • Current or ex-smokers who have a smoking history of at least 10 pack years
  • Patients with a history of at least one exacerbation.
  • Patients able to read and complete

Exclusion criteria

Exclusion Criteria:

  • Use of other drugs within 30 days
  • Patients with a history of to any of the study drugs
  • History or current diagnosis of abnormalities
  • Patients with diabetes Type I or uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range
  • Patients who have not achieved an acceptable spirometry result at Visit 1
  • Patients with a (BMI) of more than 40 kg/m2
  • Patients with lung cancer or a history of lung cancer
  • Patients with a history of of any organ system
  • Pregnant or nursing (lactating) women
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing of study treatment
  • Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers)
  • Patients that are uncontrolled or unstable on permitted therapy, who in the opinion of the investigator, have renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or haematological abnormalities which could interfere with the assessment of the efficacy and safety of the study treatment
  • Patients requiring oxygen therapy for chronic hypoxemia
  • Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1
  • Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis, bronchiectasis, sarcoidosis, interstitial lung disorder or pulmonary hypertension
  • Patients with a known diagnosis of Alpha-1 Antitrypsin deficiency.
  • Patients with history of lung surgery
  • Patients who are participating in the active phase of a supervised pulmonary rehabilitation program.
  • Patients with a history of asthma Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Budesonide/indacaterol

    Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.

    Drug: Budesonide · Drug: Fluticasone · Drug: Indacaterol · Drug: Salmeterol

  • Active comparator
    Fluticasone / salmeterol

    Fixed combination of fluticasone and salmeterol

    Drug: Fluticasone · Drug: Salmeterol

Interventions

  • Budesonide 400 mcg twice a day via Breezhaler® device

  • Fluticasone 250 mcg twice daily via Accuhaler® device

  • Indacaterol 150 mcg once daily via Breezhaler® device

  • Salmeterol 50 mcg twice daily via Diskus® device

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis).

    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change in Health Status - mMRC

    Modified Medical Research Council scale (mMRC) questionnaire will be completed by participants. 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing

    Time frame: Baseline, week 12 and week 24

  2. Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 24 Week Treatment

    A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours.

    Time frame: 24 weeks

  3. Change From Baseline in Trough Forced Expiratory Volume in 1 Second at Week 24 (Analysis of Superiority)

    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

    Time frame: Baseline and week 24

  4. Change in Health Status - SGRQ-C

    St George's Respiratory Questionnaire short version questionnaire will be completed by participants. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life)

    Time frame: Baseline, week 12 and week 24

07

Results

Posted Apr 18, 2017

Participant flow

Participant flow — Overall Study
MilestoneBudesonide/IndacaterolFluticasone / Salmeterol
Started109113
Per-protocol set (pps)108111
Completed10396
Not completed617
Withdrew: Adverse event01
Withdrew: Non-eligible01
Withdrew: Poor compliance11
Withdrew: Death12
Withdrew: Patient decision11
Withdrew: Use of prohibited treatment03
Withdrew: Ae, study drug would be detrimental13
Withdrew: Withdrawal of informed consent10
Withdrew: Reason unknown15

Outcome measures

PrimaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis).

Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis).
LitersBudesonide/IndacaterolFluticasone / Salmeterol
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis).0.080 ± 0.0270.019 ± 0.028
Statistical analysis
  • Budesonide/Indacaterol vs Fluticasone / Salmeterol · Mixed effects General linear model · p = 0.004
SecondaryChange in Health Status - mMRC

Modified Medical Research Council scale (mMRC) questionnaire will be completed by participants. 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing

Time frame:
Baseline, week 12 and week 24
Reported as:
Least squares mean · Score on a scale
Change in Health Status - mMRC
Score on a scaleBudesonide/IndacaterolFluticasone / Salmeterol
Week 121.452 ± 0.1111.623 ± 0.113
Week 241.315 ± 0.1121.414 ± 0.115
SecondaryChange From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 24 Week Treatment

A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours.

Time frame:
24 weeks
Reported as:
Mean · Puffs
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 24 Week Treatment
PuffsBudesonide/IndacaterolFluticasone / Salmeterol
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 24 Week Treatment10.5 ± 9.5312.9 ± 12.34
SecondaryChange From Baseline in Trough Forced Expiratory Volume in 1 Second at Week 24 (Analysis of Superiority)

Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.

Time frame:
Baseline and week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Trough Forced Expiratory Volume in 1 Second at Week 24 (Analysis of Superiority)
LitersBudesonide/IndacaterolFluticasone / Salmeterol
Change From Baseline in Trough Forced Expiratory Volume in 1 Second at Week 24 (Analysis of Superiority)0.063 ± 0.0330.020 ± 0.034
SecondaryChange in Health Status - SGRQ-C

St George's Respiratory Questionnaire short version questionnaire will be completed by participants. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life)

Time frame:
Baseline, week 12 and week 24
Reported as:
Least squares mean · Score on a scale
Change in Health Status - SGRQ-C
Score on a scaleBudesonide/IndacaterolFluticasone / Salmeterol
Week 12-8.703 ± 2.006-2.334 ± 2.053
Week 24-7.787 ± 2.308-2.523 ± 2.384

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Budesonide / Indacaterol (A)—10/109 (9.2%)24/109 (22%)
Fluticasone / Salmeterol (B)—9/113 (8%)39/113 (34.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventBudesonide / Indacaterol (A)Fluticasone / Salmeterol (B)
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders6/1092/113
PneumoniaInfections and infestations3/1091/113
Bronchial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1090/113
HaemoptysisRespiratory, thoracic and mediastinal disorders1/1090/113
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/1090/113
Acute myocardial infarctionCardiac disorders0/1091/113
BradycardiaCardiac disorders0/1091/113
Cor pulmonaleCardiac disorders0/1091/113
Nodal arrhythmiaCardiac disorders0/1091/113
CellulitisInfections and infestations0/1091/113
Most frequent other events
Most frequent other events
EventBudesonide / Indacaterol (A)Fluticasone / Salmeterol (B)
NasopharyngitisInfections and infestations11/10910/113
InfluenzaInfections and infestations6/10910/113
HeadacheNervous system disorders1/1099/113
DysphoniaRespiratory, thoracic and mediastinal disorders3/1098/113
Urinary tract infectionInfections and infestations3/1097/113
ArthralgiaMusculoskeletal and connective tissue disorders1/1097/113
Back painMusculoskeletal and connective tissue disorders1/1096/113

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Budesonide/IndacaterolFluticasone / SalmeterolTotal
Mean67.1 ± 967.3 ± 8.4567.2 ± 8.70
Sex: Female, Male
Sex: Female, Male(Participants)Budesonide/IndacaterolFluticasone / SalmeterolTotal
Female415495
Male6859127
08

Study locations

25 sites
  • Novartis Investigative Site
    Caba, Buenos Aires C1056ABJ, Argentina
  • Novartis Investigative Site
    Florida, Buenos Aires B1602DQD, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires 1900, Argentina
  • Novartis Investigative Site
    Vicente Lopez, Buenos Aires B1638AAI, Argentina
  • Novartis Investigative Site
    Zarate, Buenos Aires 2800, Argentina
  • Novartis Investigative Site
    Santa Rosa, La Pampa, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1125ABE, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, C1425FVH, Argentina
  • Novartis Investigative Site
    Salta, 4000, Argentina
  • Novartis Investigative Site
    Rio de Janeiro, RJ 021941-617, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90880-480, Brazil
  • Novartis Investigative Site
    Sao Bernardo do Campo, SP 09750-420, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01244-030, Brazil
  • Novartis Investigative Site
    Santiago, Region Metropolitana 8431633, Chile
  • Novartis Investigative Site
    Rancagua, 2841959, Chile
  • Novartis Investigative Site
    Santo Domingo, Republica Dominicana 10205, Dominican Republic
  • Novartis Investigative Site
    Santo Domingo, Republica Dominicana, Dominican Republic
  • Novartis Investigative Site
    Guayaquil, Guayas 412, Ecuador
  • Novartis Investigative Site
    San Pedro Sula, 21102, Honduras
  • Novartis Investigative Site
    Tegucigalpa, Honduras
  • Novartis Investigative Site
    Mexico, Distrito Federal 03310, Mexico
  • Novartis Investigative Site
    Mexico, Distrito Federal 06760, Mexico
  • Novartis Investigative Site
    Mexico, Distrito Federal 14050, Mexico
  • Novartis Investigative Site
    León, Guanajuato 37000, Mexico
  • Novartis Investigative Site
    Panama City, Panamá, Panama
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Jan 2016, 19 months.

Results were first posted in Apr 2017, 1 year 2 months after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 19 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2014
First posted
Feb 5, 2014
StartActual
May 30, 2014
Primary completionActual
Jan 26, 2016
CompletionActual
Jan 26, 2016
Results first posted
Apr 18, 2017
Last update
Apr 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02055352
Responsible party
Sponsor
First posted
Feb 5, 2014
Start date
May 30, 2014
Primary completion
Jan 26, 2016
Completion
Jan 26, 2016
Results posted
Apr 18, 2017
Last update
Apr 18, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Indacaterol

Start the discussion